ASH 2010

Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Bosutinib has therapeutic potential in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic-phase (CP) chronic myeloid leukemia (CML) with resistance to—or, particularly, intolerance to—other second-generation tyrosine kinase inhibitor (TKI) therapies, results of an open-label, phase 1/2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found.

Patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH). Using Hestia criteria, however, they may be selected and safely treated as outpatients, results of a clinical study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Both dasatinib (DAS) and imatinib (IM) are highly effective and generally well tolerated in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP), results of an open-label phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Consolidation with yttrium-90 ibritumomab tiuxetan following dose-dense cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (CHOP-R) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) converted partial remissions (PR) to complete remissions (CR) and maintained durable responses with acceptable toxicity, according to a study presented at the 52nd American Society of Hematology Annual Meeting and Exposition..

Updated results from the phase 3b MAXIMA study provides additional support for utilizing rituximab maintenance every 2 months for 2 years following rituximab-containing induction therapy for patients with newly diagnosed or previously treated follicular lymphoma (FL). The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

A study by Ronald Sobecks, MD, and colleagues at the Cleveland Clinic in Cleveland, Ohio, has been found that using IV busulfan (Bu) instead of oral Bu reduces variability in drug exposure and potentially improves safety. The study was presented at the 52nd American Society of Hematology Meeting and Exposition.

Hyperglycemia occurring during front-line treatment with nilotinib was usually mild, transient, manageable, and did not lead to treatment discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP) with or without preexisting type 2 diabetes, according to a study presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

In patients with relapsed follicular lymphoma (FL), the addition of weekly bortezomib (Vc) to rituximab (R) was associated with statistically significant improvements in progression-free survival (PFS), response rate, and time to next anti-lymphoma treatment, results of a randomized phase 3 trial presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Bendamustine plus rituximab (B-R) demonstrated a superior progression-free survival benefit in patients with relapsed follicular, indolent, or mantle cell lymphomas when compared with fludarabine plus rituximab (F-R), final results of a randomized phase 3 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have confirmed.